|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
90,630,000 |
Market
Cap: |
15.17(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$129.52 - $242.06 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 664 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
100,397 |
100,397 |
5,364,251 |
5,588,274 |
Total Sell Value |
$15,909,372 |
$15,909,372 |
$1,039,781,980 |
$1,085,894,829 |
Total People Sold |
2 |
2 |
8 |
9 |
Total Sell Transactions |
6 |
6 |
20 |
54 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Huang Jane |
CMO, Hematology |
|
2019-03-11 |
4 |
AS |
$130.00 |
$333,450 |
D/D |
(2,565) |
0 |
|
- |
|
Huang Jane |
CMO, Hematology |
|
2019-03-11 |
4 |
OE |
$29.49 |
$75,642 |
D/D |
2,565 |
2,565 |
|
- |
|
Huang Jane |
CMO, Hematology |
|
2019-03-07 |
4 |
AS |
$140.50 |
$9,976 |
D/D |
(71) |
0 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2019-03-06 |
4 |
AS |
$150.00 |
$15,000 |
I/I |
(100) |
100 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2019-03-05 |
4 |
AS |
$150.55 |
$945,454 |
I/I |
(6,230) |
0 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2019-03-05 |
4 |
AS |
$151.54 |
$729,433 |
D/D |
(4,791) |
0 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2019-03-04 |
4 |
AS |
$150.77 |
$1,481,625 |
I/I |
(9,790) |
0 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2019-03-04 |
4 |
AS |
$151.34 |
$697,426 |
D/D |
(4,588) |
0 |
|
- |
|
Wang Xiaodong |
Director |
|
2019-03-01 |
4 |
AS |
$150.00 |
$150,000 |
D/D |
(1,000) |
0 |
|
- |
|
Wang Xiaodong |
Director |
|
2019-03-01 |
4 |
AS |
$138.53 |
$584,125 |
I/I |
(4,000) |
0 |
|
- |
|
Peterson Amy C. |
CMO, Immuno-oncology |
|
2018-12-18 |
4 |
AS |
$131.74 |
$1,356,312 |
D/D |
(10,141) |
0 |
|
- |
|
Peterson Amy C. |
CMO, Immuno-oncology |
|
2018-12-18 |
4 |
OE |
$29.10 |
$295,103 |
D/D |
10,141 |
10,141 |
|
- |
|
Peterson Amy C. |
CMO, Immuno-oncology |
|
2018-12-17 |
4 |
AS |
$130.37 |
$1,317,224 |
D/D |
(9,859) |
0 |
|
- |
|
Peterson Amy C. |
CMO, Immuno-oncology |
|
2018-12-17 |
4 |
OE |
$29.10 |
$286,897 |
D/D |
9,859 |
9,859 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2018-12-10 |
4 |
AS |
$133.57 |
$561,863 |
I/I |
(4,138) |
0 |
|
- |
|
Wang Xiaodong |
Director |
|
2018-12-03 |
4 |
AS |
$150.98 |
$762,061 |
D/D |
(5,000) |
0 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2018-11-28 |
4 |
AS |
$143.71 |
$1,304,862 |
I/I |
(8,865) |
4,138 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2018-11-27 |
4 |
AS |
$139.57 |
$1,626,743 |
I/I |
(11,252) |
13,003 |
|
- |
|
Wang Xiaodong |
Director |
|
2018-11-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
89,999 |
7,773,608 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2018-11-26 |
4 |
AS |
$134.98 |
$1,262,430 |
I/I |
(9,078) |
24,255 |
|
- |
|
Huang Jane |
CMO, Hematology |
|
2018-11-26 |
4 |
AS |
$139.58 |
$418,750 |
D/D |
(3,000) |
0 |
|
- |
|
Huang Jane |
CMO, Hematology |
|
2018-11-26 |
4 |
OE |
$29.49 |
$88,470 |
D/D |
3,000 |
3,000 |
|
- |
|
Glazer Donald W. |
Director |
|
2018-11-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
9,414 |
4,127,526 |
|
- |
|
Wang Xiaodong |
Director |
|
2018-11-19 |
4 |
AS |
$122.55 |
$621,490 |
D/D |
(5,000) |
0 |
|
- |
|
Peterson Amy C. |
CMO, Immuno-oncology |
|
2018-11-12 |
4 |
AS |
$111.10 |
$1,360,349 |
D/D |
(12,067) |
0 |
|
- |
|
527 Records found
|
|
Page 16 of 22 |
|
|